CD209 and hematologic disorder: Three studies have demonstrated that CLEC7A (Dectin-1) or CD209 (DC-SIGN) variants are associated with the development of IA in patients with hematologic malignancies (Oberhofer, 1979; Sainz et al., 2010b, 2012), and this is further supported by a study finding decreased CLEC7A expression in hematologic malignancy patients with IA (Camargo et al., 2015).